NZ749545A - Composition for treatment and/or nutrition of poultry - Google Patents
Composition for treatment and/or nutrition of poultryInfo
- Publication number
- NZ749545A NZ749545A NZ749545A NZ74954517A NZ749545A NZ 749545 A NZ749545 A NZ 749545A NZ 749545 A NZ749545 A NZ 749545A NZ 74954517 A NZ74954517 A NZ 74954517A NZ 749545 A NZ749545 A NZ 749545A
- Authority
- NZ
- New Zealand
- Prior art keywords
- feed
- composition according
- gos
- composition
- lactobacillus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- 244000144977 poultry Species 0.000 title claims abstract description 23
- 230000035764 nutrition Effects 0.000 title abstract description 11
- 235000016709 nutrition Nutrition 0.000 title abstract description 11
- 241000287828 Gallus gallus Species 0.000 claims abstract description 65
- 230000000529 probiotic Effects 0.000 claims abstract description 42
- 239000006041 probiotic Substances 0.000 claims abstract description 42
- 235000018291 probiotics Nutrition 0.000 claims abstract description 42
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 37
- 239000000463 material Substances 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 241001468157 Lactobacillus johnsonii Species 0.000 claims abstract description 9
- 241000134861 Ruminococcus sp. Species 0.000 claims abstract description 9
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 8
- 229940001882 Lactobacillus reuteri Drugs 0.000 claims abstract description 8
- 241001227086 Anaerostipes Species 0.000 claims abstract description 5
- 241000801626 Collinsella tanakaei Species 0.000 claims abstract description 4
- 241001495404 Lactobacillus pontis Species 0.000 claims abstract description 4
- 241000191998 Pediococcus acidilactici Species 0.000 claims abstract description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 113
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 111
- 150000002482 oligosaccharides Polymers 0.000 claims description 43
- 229920001542 oligosaccharide Polymers 0.000 claims description 42
- 241000894006 Bacteria Species 0.000 claims description 41
- 235000019754 Grower Diet Nutrition 0.000 claims description 26
- 239000007858 starting material Substances 0.000 claims description 26
- 239000006188 syrup Substances 0.000 claims description 23
- 235000020357 syrup Nutrition 0.000 claims description 23
- 230000001580 bacterial Effects 0.000 claims description 18
- 241000186660 Lactobacillus Species 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 229940039696 Lactobacillus Drugs 0.000 claims description 12
- 229920001277 pectin Polymers 0.000 claims description 10
- 235000015097 nutrients Nutrition 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 150000003045 fructo oligosaccharides Chemical class 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 5
- 206010039447 Salmonellosis Diseases 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 241001058146 Erium Species 0.000 claims description 4
- 230000002496 gastric Effects 0.000 claims description 4
- 229940038704 Clostridium perfringens Drugs 0.000 claims description 3
- 241000193468 Clostridium perfringens Species 0.000 claims description 3
- 241001464956 Collinsella Species 0.000 claims description 3
- 241001464948 Coprococcus Species 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 241000605947 Roseburia Species 0.000 claims description 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 230000001717 pathogenic Effects 0.000 claims description 2
- 230000001551 toxigenic Effects 0.000 claims description 2
- 231100000033 toxigenic Toxicity 0.000 claims description 2
- 241001205141 Bifidobacterium animalis subsp. lactis V9 Species 0.000 claims 1
- 241000218492 Lactobacillus crispatus Species 0.000 abstract description 17
- 241000398180 Roseburia intestinalis Species 0.000 abstract description 4
- 241001522777 Anaerostipes butyraticus Species 0.000 abstract description 3
- 241001478240 Coccus Species 0.000 abstract description 3
- 241000220677 Coprococcus catus Species 0.000 abstract description 3
- 208000004232 Enteritis Diseases 0.000 abstract description 3
- 230000001338 necrotic Effects 0.000 abstract description 3
- 241001557932 Butyricicoccus Species 0.000 abstract 2
- 241000605980 Faecalibacterium prausnitzii Species 0.000 abstract 2
- 229940118852 Bifidobacterium animalis Drugs 0.000 abstract 1
- 241001134770 Bifidobacterium animalis Species 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 17
- 241000271566 Aves Species 0.000 description 15
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 241000736262 Microbiota Species 0.000 description 11
- 229920002973 ribosomal RNA Polymers 0.000 description 11
- 229940088598 Enzyme Drugs 0.000 description 10
- 235000005911 diet Nutrition 0.000 description 10
- 235000019753 Finisher Diet Nutrition 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 8
- JYJIGFIDKWBXDU-MNNPPOADSA-N Inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 8
- 229920001202 Inulin Polymers 0.000 description 8
- 229940029339 Inulin Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 108020004465 16S Ribosomal RNA Proteins 0.000 description 7
- 240000007842 Glycine max Species 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- 229960003646 lysine Drugs 0.000 description 7
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 7
- 235000019749 Dry matter Nutrition 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- GUBGYTABKSRVRQ-YOLKTULGSA-N Maltose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 GUBGYTABKSRVRQ-YOLKTULGSA-N 0.000 description 6
- 241000209140 Triticum Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 235000021307 wheat Nutrition 0.000 description 6
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- -1 d-galactosyl Chemical group 0.000 description 5
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2S,3R,4S,5R,6R)-2-[(2R,3S,4R,5R,6R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N Lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N Linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 4
- 101700051122 XYLD Proteins 0.000 description 4
- 101700001256 Xyn Proteins 0.000 description 4
- 230000003115 biocidal Effects 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 4
- 101710042134 hdac1-a Proteins 0.000 description 4
- 229960000511 lactulose Drugs 0.000 description 4
- 230000002906 microbiologic Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000004450 types of analysis Methods 0.000 description 4
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N α-D-galactose Chemical class OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 229920002287 Amplicon Polymers 0.000 description 3
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- 210000004534 Cecum Anatomy 0.000 description 3
- 210000002421 Cell Wall Anatomy 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 3
- 229960003067 Cystine Drugs 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- GZCGUPFRVQAUEE-KCDKBNATSA-N D-(+)-Galactose Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-KCDKBNATSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101710008404 GAPDH Proteins 0.000 description 3
- 102100006425 GAPDH Human genes 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine zwitterion Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 201000002674 obstructive nephropathy Diseases 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 238000005918 transglycosylation reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 108010011619 6-Phytase Proteins 0.000 description 2
- 101710017630 AF_0914 Proteins 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 101710014056 CHT1 Proteins 0.000 description 2
- 241000252983 Caecum Species 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 240000008051 Cichorium intybus Species 0.000 description 2
- 235000007542 Cichorium intybus Nutrition 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K Dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 101710037135 GAPC2 Proteins 0.000 description 2
- 101710037116 GAPC3 Proteins 0.000 description 2
- 101710025049 GAPDG Proteins 0.000 description 2
- 101710010461 Gapdh1 Proteins 0.000 description 2
- 229940021015 I.V. solution additive Amino Acids Drugs 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 235000019738 Limestone Nutrition 0.000 description 2
- 101710025050 MK0970 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000003705 Ribosomes Anatomy 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 235000015076 Shorea robusta Nutrition 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229940029983 VITAMINS Drugs 0.000 description 2
- 235000006085 Vigna mungo var mungo Nutrition 0.000 description 2
- 240000005616 Vigna mungo var. mungo Species 0.000 description 2
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 2
- 101700006119 XYL1 Proteins 0.000 description 2
- 101700047052 XYLA Proteins 0.000 description 2
- 101700065756 XYN4 Proteins 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 101710025091 cbbGC Proteins 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000003224 coccidiostatic agent Substances 0.000 description 2
- 230000001332 colony forming Effects 0.000 description 2
- 230000002596 correlated Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 101710025070 gapdh-2 Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000006028 limestone Substances 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 108010048769 pullulanase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- UKNAYQWNMMGCNX-UHFFFAOYSA-N sodium;[hydroxy(phenyl)methyl]-oxido-oxophosphanium Chemical compound [Na+].[O-][P+](=O)C(O)C1=CC=CC=C1 UKNAYQWNMMGCNX-UHFFFAOYSA-N 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamins Natural products 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 101700065693 xlnA Proteins 0.000 description 2
- 101700006979 xyl2 Proteins 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- 150000004823 xylans Chemical class 0.000 description 2
- 101710017636 xynS20E Proteins 0.000 description 2
- 229920001670 16S ribosomal RNA Polymers 0.000 description 1
- 101700075385 ARSI Proteins 0.000 description 1
- 241001553178 Arachis glabrata Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 229940015062 Campylobacter jejuni Drugs 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N Diethylpyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 229940096118 Ella Drugs 0.000 description 1
- 241001608234 Faecalibacterium Species 0.000 description 1
- 210000003746 Feathers Anatomy 0.000 description 1
- 210000002683 Foot Anatomy 0.000 description 1
- 229940113296 Fortical Drugs 0.000 description 1
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical class C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 1
- 208000007446 Hip Dislocation Diseases 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 102100008982 IL17A Human genes 0.000 description 1
- 101710003110 IL17A Proteins 0.000 description 1
- 101700007032 IL17F Proteins 0.000 description 1
- 102100015975 IL17F Human genes 0.000 description 1
- 229960000310 ISOLEUCINE Drugs 0.000 description 1
- 210000003405 Ileum Anatomy 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 229960005337 Lysine Hydrochloride Drugs 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N Mannan Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 238000002817 Miles and Misra method Methods 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 108020004418 Ribosomal RNA Proteins 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 101710022687 SERPINA3 Proteins 0.000 description 1
- 102100019205 SERPINA3 Human genes 0.000 description 1
- BBBFJLBPOGFECG-UHFFFAOYSA-N Salmon calcitonin Chemical compound C=1N=CNC=1CC(C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(C(C)O)C(=O)NC(CC=1C=CC(O)=CC=1)C(=O)N1C(CCC1)C(=O)NC(CCCNC(N)=N)C(=O)NC(C(C)O)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CO)C(=O)NCC(=O)NC(C(C)O)C(=O)N1C(CCC1)C(N)=O)NC(=O)C(CC(C)C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(C(C)C)NC(=O)C1CSSCC(N)C(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)N1 BBBFJLBPOGFECG-UHFFFAOYSA-N 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N Stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- FLUADVWHMHPUCG-OVEXVZGPSA-N Verbascose Natural products O(C[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](OC[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]3(CO)[C@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 FLUADVWHMHPUCG-OVEXVZGPSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 150000004783 arabinoxylans Chemical class 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 101700006050 ccdA Proteins 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 230000000112 colonic Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000000378 dietary Effects 0.000 description 1
- 239000006047 digesta Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229920005618 ethylene copolymer bitumen Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 101700000038 mpas Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000004466 pelleted feed Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 229920002776 polycyclohexyl methacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 229960000200 ulipristal Drugs 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- FLUADVWHMHPUCG-SWPIJASHSA-N verbascose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)O3)O)O2)O)O1 FLUADVWHMHPUCG-SWPIJASHSA-N 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N β-D-galacturonic acid Chemical group O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
Abstract
composition for the treatment and/or nutrition of poultry such as broiler chickens is disclosed as comprising (i) one more probiotics which are commensal selected from one or more of Bifidobacterium animalis, Collinsella tanakaei, Lactobacillus reuteri, Anaerostipes, Lactobacillus crispatus, Pediococcus acidilactici, Lactobacillus pontis, Faecalibacterium prausnitzii, Coprococcus catus, Roseburia intestinalis, Anaerostipes butyraticus, Butyricicoccus, Lactobacillus johnsonii, and Ruminococcus sp.; and (ii) a prebiotic material. The application also discloses the use of such a composition for the treatment of enteric disease in poultry, such as necrotic enteritis. coccus acidilactici, Lactobacillus pontis, Faecalibacterium prausnitzii, Coprococcus catus, Roseburia intestinalis, Anaerostipes butyraticus, Butyricicoccus, Lactobacillus johnsonii, and Ruminococcus sp.; and (ii) a prebiotic material. The application also discloses the use of such a composition for the treatment of enteric disease in poultry, such as necrotic enteritis.
Description
COMPOSITION FOR TREATMENT AND/OR NUTRITION OF POULTRY
The present invention relates to itions for use in the treatment and/or nutrition of
poultry, such as broiler chickens (Gallus gallus domesticus).
Broiler chickens are the most widely farmed animals. Around 50 billion chickens are
reared each year for global consumption. Chicken g on an industrial scale ts
significant challenges both of a practical and animal welfare nature. Birds which are densely
stocked, even in a free—range environment, will be apt to transmit bacterial disease. Enteric
bacterial infections such as Campylobacter jejuni are both prevalent and undesirable in broilers.
One of the major indications for the use of antibiotics in broilers is enteric disease (Journal of
Antimicrobial herapy, Vol 61, Issue 4, Pp947-952).
Studies have demonstrated that certain commensal bacteria present in the microbiota of
y such as broilers can have a beneficial effect upon their g, by improving their gut
health and thereby their performance in terms of feed conversion ratio (FCR) and rate of weight
gain (see for example, “Microbiota of the chicken gastrointestinal tract: influence on health,
productivity and disease”, Stanley et al Appl, Microbiol. Biotechnol. (2014) 98:4301-4310, and
Stanley D, Hughes RJ, Geier MS and Moore RJ(2016) Bacteria within the gastrointestinal tract
microbiota correlated with improved growth and feed conversion: Challenges presented for the
identification of performance enhancing probiotic bacteria. Front. Microbiol. 7:187.
doi:10.3389/fmicb.2016.00187).
Reference herein to the bacteria as being commensal refers to their presence within the
gastrointestinal tract of the majority of the broiler populations. However, it is the case that
because of the environment, diet, broiler stock or other factors that either a particular broiler
population or, for whatever reason, a proportion of broilers within a tion, have an altered
iota or lack one or more of those bacteria.
It would therefore be desirable to identify specific probiotics for poultry such as broilers
comprising one or more such ia. The use of such a probiotic will, ore, result in an
improvement in the profile of commensal bacteria within a r chicken, since it will then
include one or more of these ia shown to be beneficial to g, which have a beneficial
effect upon broiler health and performance
Therefore, according to the present invention, there is provided a composition comprising:
(i) a tic selected from one or more of the bacteria bacterz’um animalis,
Collinsella tanakaei, Lactobacillus reuteri, Anaerostipes, Lactobacillus crispatus,
Pediococcus acidilactici, Lactobacillus pontis, ibacterium prausnitzii,
Coprococcus catus, Roseburia intestinalis, Anaerostipes butyraticus,
cicoccus, Lactobacillusjohnsonii, andRuminococcus Sp. , and
(ii) a prebiotic al.
The composition of the invention may comprise the specific probiotic bacterial strain
Lactobacillus crispatus DC2l.l (NCIlVfl3 42771), deposited on 23 June 2017 at NCIMB d,
Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA,. United Kingdom.
The composition of the invention may comprise the specific probiotic bacterial strain
acillusjohnsonii DC22.2 (NCIMB 42772), deposited on 23 June 2017 at NCIlVfl3 Limited,
Ferguson Building, Craibstone , Bucksburn, Aberdeen, AB21 9YA,. United Kingdom.
The composition of the invention may comprise the specific probiotic bacterial strain
Lactobacillus i DClB4 (NCIMB 42773), deposited on 23 June 2017 at NCIMB Limited,
Ferguson ng, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA,. United Kingdom.
The composition of the invention may comprise the specific probiotic bacterial strain
Ruminococcus sp. DC3A4 (NCIlVfl3 42774), deposited on 23 June 2017 at NCIlVfl3 Limited,
Ferguson Building, Craibstone Estate, Bucksburn, Aberdeen, AB21 9YA,. United Kingdom.
The probiotic bacteria used in the ion are typically sal bacteria.
An e of the performance objectives for broiler chickens can be found in Aviagen
Ross 308 Broiler Performance Objectives 2014 documentation.
An example of the nutrition specifications for broiler chickens can be found in Aviagen
Ross 308 Broiler Nutrition Specifications 2014 documentation.
Prebiotic materials are defined by the US Food and Drug Administration as being non-
ible food ingredients that beneficially affect the host by selectively stimulating the growth
and/or activity of one or a limited number of ia in the colon.
The definition provided by the US Food and Drug Administration has been reviewed and
modified based on three criteria:
(a) resistance to gastric acidity, hydrolysis by mammalian enzymes and intestinal
absorption,
(b) fermentation by intestinal microflora;
(c) selective stimulation of the growth and/or activity of intestinal bacteria ated with
health and well-being;
In view of this, prebiotic materials are defined by Gibson et a]. (2004) (Gibson, G. R,
Probert, H. M, Loo, J. V., Rastall, R. A., andRoberfroia’, M B. (2004) “Dietary modulation of
the human colonic microbiota: updating the concept ofprebiotics ” Nutrition Research s,
17(2) 259-2 75) as being a selectively fermented ingredient that allows specific changes, both in
the composition and/or activity in the gastrointestinal microflora that confers benefits upon host
well—being and health.
Examples of prebiotics are inulin, fructo-oligosaccharides (also known as oligofructose)
which is a partial hydrolysate of inulin, galacto—oligosaccharides (GOS) (also known as
alacto-oligosaccharides), lactulose, lactosucrose, isomalto-oligosaccharides, xylo-
oligosaccharides, arabinoxylo-oligosaccharides, gluco-oligosaccharides, mannan
oligosaccharides (MOS), soyabean oligosaccharides, and pectic oligosaccharides.
Prebiotic definitions
The following definitions provided by Gibson et a1. (2004) are ed as rd
definitions of the mentioned examples of prebiotics:
Inulin and fructo-oligosaccharides
, or the hydrolysed fructo-oligosaccharides, are described as either an:
o ucopyranosyl-[B—D-fructofuranosyl]n-1—B-D-fructofuranoside (GFn); or a
o B-D—fructopyranosyl-[B-D -fructofi1ranosyl]n.1—B-D-fructofuranoside.
The fructosyl—glucose linkage is always B(2<—l) as in sucrose, but the fructosyl—fructose
linkages are B(l<—2).
There are a number of sources of inulin. A major source of inulin is chicory. Chicory inulin
is composed of a mixture of oligomers and polymers in which the degree of polymerisation (DP)
varies from 2 - 60 with an average DP Z 12.
Fructo-oligosaccharides (oligofructose) are formed by the partial (enzyme catalysed or
al) hydrolysis of inulin giving a mixture of both a—D-glucopyranosyl-[B-D-
fructofuranosyl]nB-D-fructofuranoside (GFn) and B-D-fructopyranosyl-[B—D -fructofi1ranosyl]n_
1-B-D-fructofiiranoside molecules with a DP of 2 - 7.
Galacto-oligosaccharides (GOS)
GOS are a e of accharides formed by the enzyme (B-galactosidase) catalysed
transglycosylation of lactose and uent galacto-oligosaccharides. The oligosaccharides are
often considered to be of the form (gal)n-glc with DP = 2 - 8 and B(l—>6), ) and B(l—>4)
mixed linkages; however, galactans with the same linkages can be present. The product mixtures
depend upon the enzymes used and the reaction conditions.
GOS (galacto—oligosaccharide) is sold by Dairy Crest Ltd under the trade name Nutrabiotic®
GOS for animal feed applications.
Lactulose
Lactulose is manufactured by the isomerisation (often chemical isomerisation) of lactose to
generate the disaccharide galactosyl-B(l—>4)-fructose.
Lactosucrose
Lactosucrose is_produced from a mixture of lactose and sucrose in an enzyme (for example
B-fructofuranosidase) catalysed lycosylation reaction. The fructosyl residue is transferred
from sucrose to the C 1 position of the glucose moiety in the lactose, producing a non-reducing
oligosaccharide.
Isomalto-oligosaccharides
to-oligosaccharides are_manufactured from oligosaccharides, or maltose (both
of which are produced from starch by the combined reactions catalysed by oz—amylase and
pullulanase, or B-amylase and pullulanase). The malto-oligosaccharides and maltose are
converted into 0t(l—>6)—linked isomalto—oligosaccharides by enzyme (u—glucosidase or
transglucosidase) catalysed transglycosylation reactions.
Xylo-oligosaccharides and arabinoxylo-oligosaccharides
ligosaccharides and arabinoxylo-oligosaccharides are_made from wood or cereal non-
starch materials (corn cobs, wheat bran etc.). Depending upon various xylan s used, and the
method of production, the structures vary in degree of polymerization, monomeric units, and
types of linkages. Generally, xylo-oligosaccharides are es of oligosaccharides formed from
xylose residues, typically DP = 2 - lO, linked through B(l—>4)-linkages. Xylan is usually found in
combination with other side groups such as ucopyranosyl uronic acid or its thyl
derivative, acetyl groups or arabinofiiranosyl (giving arabinoxylo-oligosaccharides) residues.
Xylo-oligosaccharides and arabinoxylo-oligosaccharides are produced by chemical methods,
enzyme catalysed hydrolysis (e.g. the hydrolysis of arabinoxylans catalysed by combinations of
endo-l,4-B-xylanases, B-xylosidases, arabinofuranosidases and yl esterases) or a
combination of chemical and enzyme catalysed treatments.
Gluco-oligosaccharides
Gluco—oligosaccharides are often referred to as a—GOS. These are mixed u—gluco-
oligosaccharides produced in ons sed by dextran e in fermentation processes
(fermentation of Leuconostoc mesenteroides) or in the enzyme catalysed transglycosylation
reactions involving sucrose in the presence of maltose. This gives oligosaccharides with a range
of oe—linkages (e. g. yl-OL( l —>2)-glucosyl-0t( l —>6)—glucosyl-0t( l —>4)-glucose).
Mannan oligosaccharides (MOS)
Mannan accharides are normally obtained from the cell walls of the yeast
Saccharomyces cerevisiae. and presented as products of different levels of purity. In the yeast cell
wall, mannan oligosaccharides are present as:
0 complex molecules that are linked to the cell wall proteins as -O and -N glycosyl groups;
0 nnans made up of an 0t—(l,6)—D-mannose backbone to which are linked Ot-(l,2)-
and 0t-(l,3)- D-mannose branches (1 - 5 mannosyl groups long).
Soyabean oligosaccharides
Soyabean oligosaccharides are d—galactosyl sucrose derivatives (eg. raffinose, stachyose,
verbascose). They are isolated from soya beans and concentrated for the final product
formulation.
Pectic oligosaccharides
Pectic oligosaccharides (POS) are obtained by pectin depolymerization by either enzyme
(pectin hydrolases and lyases) catalysed reactions or acid (typically) hydrolysis. Given that
pectins are x ramified heteropolymers made up of:
o a smooth region of linear backbone of 4)—linked D-galacturonic acid units which
can be randomly acetylated and/or methylated);
o hairy regions of rhamnogalacturonan type I and rhamnogalacturonan type II;
the structural diversity of the pectic oligosaccharides from pectin hydrolysis is high.
The prebiotic materials useful in the invention may be naturally or non-naturally
occurring. The probiotics are responsive to prebiotics, with the populations of the probiotics
sing due to the presence of the prebiotic material, and the presence of the prebiotic material
correlates with improved r performance, including weight gain during rearing.
The one or more bacteria are typically selected from the more specific bacterial s, as
fied as nearest cultural examples: Bifidobacz‘erium animalz's subsp. lactis str. V9, Collinsella
tanakaei str. YIT 12064, Lactobacillus reulerl' str. BCSl36, Anaerostz'pes sp. str. 35-7,
acillus crispalus str. STl, acillus crispaz‘us str. DC21, Lactobacillus crispatus str.
DC2l.l (NCIlVfl3 42771), Lactobacillus johnsonii str. DC22.2 (NCIlVfl3 42772), acz'llus
reuterl' str. DClB4 (NCIMB , and Ruminococcus Sp. str. DC3A4 (NCIlVfl3 42774).
The probiotic bacteria used in the invention were identified as being up-regulated in a
broiler trial treatment that contained galacto-oligosaccharides (GOS) in the feed, ed to a
control feed.
The one or more bacteria may be selected from their nearest (based on sequence)
equivalents. Identification of the bacteria included in the composition of the invention is
based on Operational Taxonomic Units (OTUs) identified from 168 rDNA sequences from
the V4 region of the microbiome. Specifically, 16S rRNA gene sequences were aligned
against a nce alignment based on the SILVA rRNA database and clustered into OTUs
with an average neighbor clustering algorithm. The nearest l6S rRNA gene sequence
identities to the OTUs are reported on the basis of BLASTn searches if data matches are from
type cultures with a BLAST identity 299%. The laboratory and bioinformatic techniques
used to identify the bacteria included in the composition of the invention is described as
follows:
Histology
Samples of ileum for histological assessment were examined from birds from each relevant
treatment. The fixed tissue samples were ated through a series of alcohol solutions, cleared
in , and finally embedded in paraffin wax (Microtechnical Services Ltd, Exeter, UK).
Sections (3 to 5 pm thick) were prepared and d with modified hematoxylin and eosin
(H&E) using standard protocols. After staining, the slides were scanned by NanoZoomer Digital
Pathology System (Hamamatsu, Welwyn Garden City, UK). Measurements of villus height and
crypt depth were made using the NanoZoomer Digital Pathology Image Program atsu) of
well-oriented villi d at 40 X magnification. Villus height was measured from the tip of
the villus to the crypt opening and the associate crypt depth was measured from the base of the
crypt to the level of the crypt opening. The ratio of villus height to relative crypt depth (V:C
ratio) was calculated from these measurements.
RNA ion and RT-qPCR of the Cytokines and ines
RNA was isolated from cecal and ileal tissue biopsies using NucleoSpin RNA isolation kit
rey—Nagel, GmbH & co. KG, Duran DE) ing to the manufacturer’s protocol with
the following modifications. Tissue samples were nized in Lysis buffer with 2.8 mm
ceramic beads (MO BIO Laboratories Inc, Carlsbad, USA) using TissueLyser II (Qiagen,
Hilden, DE) prior to subsequent purification as bed in the protocol. RNA was eluted in
DEPC treated water (Ambion ThermoFisher Scientific, UK) and stored at —80°C. RNA quality
and concentration were assessed using Nanodrop ND-lOOO Spectrophotometer (Labtech
International Ltd, Uckfield, UK). The ratio 260/280 nm was in the range of 1.79 to 2.17 with the
mean of 2. 12 ::0.01 for all RNA samples used.
Reverse Transcription was performed with lug of RNA using SuperScript II (Invitrogen
Life Technologies, Carlsbad, USA.) and random hexamers (Untergasser’s Lab 2008 accessed
online 16/12/2016; URL
http://wwwuntergasser.de/lab/protocols/cdna_synthesis_superscript_ii_vl_0.htm). Quantitative
PCR reaction was performed with cDNA template derived from 4 ng of total RNA in triplicate
using SYBR Green Master mix (Applied Biosystems, ThermoFisher Scientific), Cytokines and
chemokines fold change were calculated using the “comparative Cycle threshold (Ct) method”
established by the manufacturer as described by Livak, KI, and Schmittgen, TD. .
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2'AACT
Method. Methods 24, 402-408.. The e of the triplicate Ct values was used for analysis and
the target genes Ct values were normalized to those of the housekeeping gene encoding
Glyceraldehyde 3-phosphate dehydrogenase ). The RNA level of expression was
determined by qPCR using the Roche Diagnostics LightCycler 480 (Hoffmann La Roche AG,
CH). The primers used for qPCR of GAPDH, IFN—y, IL-lB, IL-4, IL-6, IL—10, IL—17A, IL-17F,
CXCLil and CXCLi2 are presented in Table 6.
DNA Extraction and PCR Amplification of 168 rRNA Gene Sequences and Microbiota Diversity
Bacterial DNA was isolated from 0.25 g cecal content using the PowerSoil DNA Isolation Kit
(MO Bio Laboratories) according to the manufacturer’s ctions. Using the isolated DNA as a
template the V4 region of the bacterial 16S rRNA gene was PCR amplified using primers 515f
(5' GTGCCAGCMGCCGCGGTAA 3 ') and 806r (5' GGACTACHVGGGTWTCTAAT 3 ’) as
described by Caporaso, J.G., Lauber, C.L., s, W.A., yons, D., Lozupone, C,A.,
Turnbaugh, P.J., et al. (2011). Global ns of 16S rRNA diversity at a depth of millions of
sequences per sample. Proc. Natl. Acad. Sci. USA. 108 Suppl 1, 4516-4522.
doi: 10.1073/pnas.1000080107.
Amplicons were then ced on the Illumina MiSeq platform using 2 x 250 bp cycles.
Prior to metagenomic analysis sequence reads with a quality score mean below 30 were removed
using q eder, R., and Edwards, R. (2011) Quality control and preprocessing of
metagenomic datasets. Bioinformalics 27, 863-864. doi: 3/bioinformatics/btr026.). The
168 rRNA sequence analysis was performed using Mothur v. 1.37.4 (Schloss, P.D., Westcott,
S.L., Ryabin, T., Hall, J.R., Hartmann, M., Hollister, E.B., et al. (2009). Introducing mothur:
open-source, platform-independent, community-supported software for describing and comparing
microbial communities. Appl. Environ. iol. 75, 7537-7541. doi: 10.1128/AEM.0154l-09.).
Analysis was performed as according to the MiSeq SOP (accessed online 08/12/2016; Kozich,
J.J and Schloss, PD. (2013). pment of a
., Westcott, S.L., Baxter, N.T., Highlander, SK,
dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the
MiSeq Illumina sequencing platform. Appl. Environ. Microbiol. 79, 5112-5120.) with the
ion that the screenseqs command used a maxlength option value similar to that of the 97.5
percentile length. The 168 rRNA gene ces were aligned against a reference alignment
based on the SILVA rRNA database (Pruesse, E., Quast, C., Knittel, K, Fuchs, B.M., Ludwig,
W.G., Peplies, J., et al. (2007). SILVA: a comprehensive online resource for quality checked and
aligned ribosomal RNA sequence data compatible with ARB. Nucl. Acids Res. 35, 7188-7196
doi: 10.1093/nar/gkm864) for use in Mothur (available at:
https://www.mothur.org/wiki/Silva_reference_f11es), and clustered into operational taxonomic
units (OTUs) with an average neighbor ring algorithm. The nearest 16S rRNA gene
sequence identities to the OTUs are reported on the basis Tn searches if data matches are
from type cultures with a BLAST identity 299%. If not, the consensus taxonomy ofthe OTUs is
reported as generated using the classifyotu command in Mothur with reference data from the
Ribosomal Database Project (version 14) (Cole, J. R., Wang, Q., Fish, J.A., Chai, B., McGarrell,
D. M., Sun, Y., et al. (2014). Ribosomal Database Project: data and tools for high throughput
rRNA analysis. Nucl. Acids Res. 42(Database , D633-D642., Wang, Q., Garrity, G, M.,
Tiedje, J. M., and Cole, J.R. (2007). Na'1've Bayesian classifier for rapid assignment of rRNA
sequences into the new bacterial my. Appl Environ Microbiol. 73, 5261-5267. doi:
,1128/AEM00062-07) adapted for use in mothur (available at:
//www.mothur.org/wiki/RDP_reference_files).
Data Analysis
ANOVA followed by Tukey's multiple comparisons test and Kruskal-Wallis test followed
by Dunn's multiple comparisons test was performed using GraphPad Prism n 7.00 for
Windows (GraphPad Software, La Jolla, USA, wwwgraphpadcom). Metastats were
implemented within Mothur (White, J.R., Nagarajan, N., and Pop, M. . Statistical methods
for detecting differentially abundant features in clinical nomic samples. PLoS Comput.
Biol. 03 52. doi: 10.1371/journal.pcbi. 1000352). Data processing and ordination were
performed using R project (R Development Core Team, 2008. R: A language and environment
for statistical ing. R Foundation for tical Computing, Vienna, a. ISBN 3-
9000510, URL http://www.R-project.org). Heatmaps were d using the heatmap.2
function ofR package gplots (Warnes, G.R., Bolker, B., Bonebakker, L., Gentleman, R., Huber,
W., Liaw, A, et a1. (2016). gplots: Various R Programming Tools for Plotting Data. R package
version 3.0.1. https://CRAN.R—project.org/package=gplots).
Ethics Statement
Studies were carried out under license and in ance with UK Animals (Scientific
Procedures) Act 1986. All procedures were approved by the Local Ethics Committee of the
University ofNottingham.
The most preferred one or more bacteria are selected from the c bacterial strains
Lactobacillus crispatus str. DC21.1 fl3 42771), Lactobacillus johnsonii str. DC22.2
(NCIlVfl3 42772), Lactobacillus reuteri str. DC1B4 (NCIlVfl3 42773), and coccus sp. str.
DC3A4 (NCIMB 42774).
Preferable compositions of the present invention are Lactobacillus crispatus str. DC21.1
(NCIlVfl3 42771) with a galacto-oligosaccharide, such as Nutrabiotic® GOS, Lactobacillus
johnsonii str. DC22.2 (NCIlVfl3 42772) with a galacto-oligosaccharide, such as Nutrabiotic®
GOS, Lactobacillus reuteri str. DC1B4 (NCIMB 42773) with a galacto-oligosaccharide, such as
Nutrabiotic® GOS, and Ruminococcus sp. str. DC3A4 (NCIMB 42774) with a ooligosaccharide
, such as Nutrabiotic® GOS.
The strains Lactobacillus tus str. DC21.1 (NCIMB , Lactobacillusjohnsonii
str. DC22.2 (NCIlVfl3 42772), Lactobacillus reuteri str. DC1B4 fl3 42773), and
Ruminococcus sp. str. DC3A4 (NCIMB 42774), are all commensal to Ross 308 broilers grown on
a standard wheat-based feed that also contains Nutrabiotic® GOS (galacto—oligosaccharide) and
produced in the poultry facility, University of Nottingham, Sutton Bonington campus, and were
isolated from digesta taken from the caecum.
The specific ial strains, as well as the bacteria (not ced), have been identified
from the microbiome of the same.
It is reported in Stanley, 0, Hughes, R. J., and Moore, R. J. (2014) “A/[icrobiota of the chicken
gastrointestinal tract: influence on health, productivity and disease” Applied Microbiology and
Biotechnology, 98 310 and Stanley D, Hughes RJ, Geier MS and Moore RJ(2016)
Bacteria within the gastrointestinal tract microbiota correlated with improved growth andfeed
conversion: Challenges ted for the fication of performance enhancing probiotic
bacteria. Frontiers in Microbiology, 7:187. doi:10.3389/fmicb.2016. 00187 that the bacteria and
specific bacterial strains are associated with good es, and/or are associated with the
microbiota of broilers that display high performance.
According to one embodiment of the invention, the composition may comprise two or
more probiotics. For example, a first probiotic preparation may be taken from a group
comprising specific facultative anaerobic commensal bacteria, for example Lactobacillus spp.
and Bifidobacterium spp., which produce acetate and lactate when acting on a tic, and a
second probiotic preparation may be taken from a group comprising specific strictly anaerobic
sal bacteria which produce butyrate ng” on the acetate and lactate produced by the
probiotic preparation of the first group. A ‘probiotic preparation’ is considered to comprise one
or more probiotic bacteria taken from the respective facultative anaerobic or strictly anaerobic
group.
According to another embodiment of the invention, the ition may comprise the
two or more probiotics in combination with only one prebiotic material. An example of a
potential combination of a composition according to this embodiment may be a first probiotic, for
example Lactobacillus spp. or acl‘erium spp., taken from a group comprising specific
facultative anaerobic commensal bacteria which e acetate and lactate when acting on the
prebiotic, and a second probiotic taken from a group comprising specific strictly anaerobic
commensal bacteria which produce butyrate ng” on the acetate and lactate produced by the
first probiotic, in combination with a tic, for example, Nutrabiotic® GOS.
The bacteria may comprise facultative anaerobic bacteria or strictly anaerobic bacteria
According to another embodiment of the invention, the composition may comprise
facultative anaerobic bacteria in ation with a prebiotic. The combination may create
acetate and lactate.
According to another embodiment of the ion, the composition may comprise strictly
anaerobic bacteria in combination with acetate and lactate. The combination may create organic
acids. The organic acids may be, for example, butyrate.
The prebiotic material used in the composition of the invention is typically substantially
stible in the gastrointestinal system of a chicken.
r aspect of the t invention was to identify specific probiotics which respond
favourably to the use of polymeric saccharide, such as an accharide sugar, as a prebiotic
material; and whose populations with the broiler intestinal tract can, therefore, be increased
by the use of such prebiotics. Therefore, the prebiotic al is typically a ric
saccharide, such as an oligosaccharide.
The oligosaccharide used in the composition of the invention may be selected from one or
more of fructooligosaccharide (also known as oligofructose) which is a partial hydrolysate of
inulin, mannanoligosaccharide (MOS), galactooligosaccharide (GOS), xylooligosaccharide,
arabinoxylanoligosaccharide, soyoligosaccharide, lactulose, lactosucrose, isomalto-
oligosaccharides, gluco-oligosaccharides, pectic oligosaccharides, and . lly, the
oligosaccharide is a galactooligosaccharide.
Galactooligosaccharides (GOS) have the general form (galactosyl)n-lactose and typically
range in size from trisaccharides to octasaccharides. Structural complexity is uced by the
different intermolecular bonds. Products said to comprise GOS therefore typically contain a
mixture of ooligosaccharides, lactose, glucose and galactose, and the term GOS is used
herein in a manner intended to encompass such products.
GOS (galacto—oligosaccharide) is sold by Dairy Crest under the trade name Nutrabiotic®
GOS for animal feed.
Typically, Nutrabiotic® GOS L is used as the prebiotic in the composition of the present
invention. Nutrabiotic® GOS L es with UK and EU Regulations and recommended purity
specifications, including heavy metals, for feed and food ingredients. An analysis of
iotic® GOS L is provided in Table 21.
The recommended inclusion, or dose, rate ofNutrabiotic® GOS in animal feed diets
depends on a number of factors. For example:
0 the animal (e. g. broiler (chicken for fattening) or piglet),
0 life cycle and the feeding regime (e. g. the different feeds being used and the duration of
their use; use, and commencement of use, of a creep (pre—starter) feed;
age of s at weaning etc);
o formulation of the Nutrabiotic® GOS product and, to a lesser extent, the batch of the
Nutrabiotic® GOS product being used,
The data presented in Table 22 are recommendations based on typical feeding regimes
and ones that have been used in both research and cial trials. They can be modified as
required.
The data presented in Table 24 es an estimate of the metabolizable energy values of
Nutrabiotic® GOS L in rs and piglets.
Nutrabiotic® GOS contains no significant quantities of protein or fat, or vitamins,
minerals etc. as shown in Table 21. Nutrabiotic® GOS contains a range of carbohydrates that
are either digested as , or fermented as soluble fibre. In the context of energy value for
animal feed applications and specific animals, the definition of what is considered fibre is
complicated as an appreciable number of disaccharides present in Nutrabiotic® GOS L are
fermented. Moreover the proportion of disaccharides that are fermented will differ depending on
the animal (e. g. piglets compared to y).
Starter, grower and finisher refer to the diets at the different stages of the broiler
tion cycle. The diets correspond to the following periods (day 0 is defined as the day the
broiler chicks are “placed” in the y shed, although at day 0 the broiler chicks are usually 1
day old):
0 0 - 10 days Starter feed (sieved crumb, but can alternatively be in the form of a
mash feed)
0 11-24 days Grower feed (pellets 3 mm diam.)
0 25-35 days Finisher feed ts 3 mm diam.)
The feeds, after the mixing of all the raw materials are pelleted (after steam injection and
treatment) are extruded through a defined die to typically give a 3 mm pellet, that is the final
broiler feed.
The pelleting process may follow typical methods known to a person skilled in the art.
Suitable feed and pellet size may be known to a person skilled in the art.
Crumb refers to a crumbed (broken into crumb) pelleted feed — typically to give smaller feed
pieces that the broiler chicks can manage. A mash feed (a feed mixture that has not been pelleted)
may be used instead of a crumb feed for the started feed.
The production cycle in this e is 35 days, which is reasonably common for
experiments involving male (we only use the faster growing males to decrease the statistical
variation in experimental systems) Ross 308 birds. Poultry cycles are more complex with birds
being “harvested” at 35 — 42 days to get different weight ranges for commercial purposes.
Typically, the production cycle is 35 days, which is reasonably common for experiments
involving male Aviagen Ross 308 birds, as typically used in the present ion.
The composition of the ion typically includes an amount of between about 104
colony forming units (Cfil) to 1012 cfu, typically between about 105 cfi1 to 1010 cfu, more typically
n about 106 cfu to 108cfu, and most typically 107 cfu. CFU is essentially the number of
live bacteria added at day 9 of a trial. Preferably, the addition of CFU should not preclude the
tic being added at different times, or continuously, as part of the feed, in a cial
operation.
The composition of the invention includes a prebiotic, lly Nutrabiotic® G08.
Typically, a starter feed includes an amount of prebiotic, for example Nutrabiotic® GOS,
between about 55% to 95% (w/w) solids concentration syrup, typically between about 65% to
85% (w/w) solids concentration syrup, more typically between about 70% to 80% (w/w) solids
concentration syrup, and most lly about 75% (w/w) solids concentration syrup.
Typically, in the r feed the tic, for example Nutrabiotic® GOS, is added at a
dose rate between about 0.50% to 5.00% (w/w complete starter feed), typically between about
1.50% to 3.50% (w/w complete starter feed), more typically between about 2.00% to 3.00%, even
more typically between about 2.20% to 2.60% (w/w complete starter feed), even more typically
between about 2.40% to 2.50%, and most typically about 2.47% (w/w complete starter feed).
Typically, a grower feed includes an amount of prebiotic, for example Nutrabiotic® GOS,
between about 55% to 95% (w/w) solids concentration syrup, lly between about 65% to
85% (w/w) solids concentration syrup, more lly between about 70% to 80% (w/w) solids
concentration syrup, and most typically about 75% (w/w) solids concentration syrup.
lly, in the grower feed the prebiotic, for example Nutrabiotic® GOS, is added at a
dose rate between about 0.20% to 5.00% (w/w complete grower feed), typically between about
0.60% to 3.50% (w/w complete grower feed), more typically between about 0.90% to 2.80%,
even more lly between about 1.10% to 2.00% (w/w complete grower feed), even more
typically between about 1.15% to 1.60%, even more typically between about 1.20% to 1.40%,
and most lly about 1.24% (w/w complete grower feed).
Typically, the prebiotic, for example, iotic® GOS, is not added to the finisher feed.
In a typical trial experiment, the addition of the bacteria is lly made in 0.10ml of
MRD (Maximum Recovery Diluent), giving 107 cfu (colony forming units) or viable cells, by
cloacal gavage.
A further aspect of the present ion relates to a composition as defined hereinabove
for the treatment and/or nutrition of poultry, such as broiler chickens, to which at least one of the
probiotics responds to produce an increase in population.
The composition of the invention may also fithher comprise a nutrient food source. The
nutrient food source may contain a source of protein, starch, amino acids, fat, or a combination of
any two or more thereof. The nutrient food source may also contain one or more food additives
which can be found in y feed, such as, but not limited to, vaccines, antibiotics, and
iostats, or a combination thereof. The antibiotics may be those used in treatment or as
growth promoters.
The composition of the invention, containing the tic bacteria which are responsive
to the prebiotics, and whose presence correlates with improved broiler performance, is able to
impart benefits to the development of the poultry compared with poultry which is not exposed to
the composition, such as an increased rate of growth, and/or a higher final weight, and/or a larger
ratio of kilograms of feed ed per kilogram of growth of the poultry.
The inventors have been able to show that intestinal populations of the tic
bacteria d to the administration of prebiotics, such as oligosaccharides; and that increases
in populations of one or more of the tic bacteria correlate to improved weight gain within
broilers.
Also provided by the t invention is a composition for use in the treatment of enteric
bacterial disease in poultry, the composition comprising:
(i) a probiotic selected from one or more of the bacteria baclerz’um animalis,
Collinsella Zanakaei, Lactobacillus reuteri, Anaerostipes, Lactobacillus crispatus,
Pediococcus acidilactici, Lactobacillus ponlis, ibaclerium prausnilzii,
Coprococcus cams, Roseburia intestinalis, Anaeroslipes bulyraticus,
Buzfyricicoccus, Lactobacillusjohnsonii, and Ruminococcus sp.; and
(ii) a prebiotic material.
The definitions and embodiments defined above for the composition of the invention also
apply to the composition for use in the treatment of enteric bacterial disease in poultry.
The c bacterial disease is infection by one or more of the following: Clostridium
perfringens, Salmonella spp, pathogenic and toxigenic Escherichia coli (EPEC and ETEC).
The composition of the invention may be administered in any suitable manner, including,
but not limited to, orally (via feed, which may need to be encapsulated in order to protect the
probiotic from the acidic environment in a chicken’s stomach), via intracloacal delivery (Arsi,
Donoghue, Woo-Ming, Blore and Donoghue: Intracloacal Inoculation, an Effective Screening
Method for ining the Efficacy of Probiotic Bacterial Isolates against Campylobacter
sation in Broiler Chickens, Journal of Food Protection, Vol 78, No. l 2015, Pages 209-
213), or via a spray, such as onto chicks so they consume the ition by licking their
feathers.
A r aspect of the present invention is a composition for the treatment and/or
nutrition of poultry, such as a broiler chicken, comprising one or more specific probiotics and a
prebiotic material which produce c acids in the gastrointestinal tract, which impart benefits
to the health of the broiler chickens.
All of the probiotics listed hereinabove are able to act in an strictly anaerobic manner,
while some are also able to act in a facultative anaerobic manner.
It is those (e.g. Lactobacz'llus spp. and Bg’fidobacterium spp.) which act in a facultative
anaerobic manner which produce organic acids, such as acetic and lactic acids, in the
gastrointestinal tract such as acetic and lactic acids, when fermenting the prebiotic. The probiotics
which are strict anaerobes, produce butyrate and other c acids when ed with a
prebiotic and the acetate and lactate. These probiotics include, for example, Coprococcus cams,
Roseburia inlestinalis, and Anaerostipes butyralicus, Ruminococcus Sp., Butyricz'coccus, and
Faecalibacz‘erium prausnil‘zz'i.
These bacteria are known to feed upon fibre in the gastrointestinal tract of a broiler
chicken. That feeding process generates the organic acids which are beneficial in at least two
ways. Firstly, they reduce the pH within the tract which, lly speaking, tends to assist the
growth of ial gut flora whilst simultaneously inhibiting the growth of more harmful flora.
Secondly, the acids are directly beneficial per se as nutrients to the r and so the presence of
one or more of these bacteria produces useable sources of energy.
The probiotics used in the ion serve the additional benefit of reducing populations
of harmful gut flora. Examples of such l flora are Clostridium perfringens which is known
to cause necrotic enteritis, and ella whose presence is extremely harmful to humans and
so desirably eliminated from broilers.
Although one or more of the compositions set out above can be used to treat, for example,
the presence of undesirable gut flora in broiler chickens, they may advantageously also be used in
feed compositions for prophylactic purposes.
The invention will now be described further by way of e with reference to the
following examples, which are intended to be illustrative only and in no way limiting upon the
scope of the invention.
Examples
An example of a trial experiment using the composition of the invention included the
following:
o prebiotic (Nutrabiotic® GOS) at the following dose rates:
- starter feed: Nutrabiotic® GOS a 75 %(w/w) solids concentration syrup
added at a dose rate of 2.47 %(w/w complete starter feed)
° grower feed: Nutrabiotic® GOS a 75 %(w/w) solids concentration syrup added at
WO 02671 2017/051949
a dose rate of 1.235 %(w/w complete grower feed)
finisher feed: Nutrabiotic® GOS is not added to the finisher feed;
0 Single addition of a probiotic preparation of 107 Cfil, added at day 9 of the trial.
Addition was made in 0.10 ml of MRD (Maximum Recovery Diluent) by cloacal
gavage. This method of addition was solely for the purpose to ensure proof of
concept. It is not envisaged that this method of addition would be used in a
production environment.
Table 1 provides a list of the ients in a commercially available poultry feed mixture,
with which the composition of the invention may be combined for stration to the poultry.
Table 1
EXT. HIPRO SOYA
MEAL 32.5 30.8 25.3
LIMESTONE
GRANULES 0.60 0.40 0.40
SOYABEAN OIL 3.65 5.52 5.60
LYSINE HCL 0.296 0.119 0.123
METHIONINE DL 0362 0.263 0.231
DICALCIUM
PHOSPHATE 1.59 1.28 1.12
SODIIHVI
BICARBONATE 0.269 0.188 0.193
SALT 0.150 0.210 0.210
THREONINE 0.134 0.054 0.054
TM — Blank Premix for
Broiler Formulation 0.400 0.400 0.400
RONOZYME® P5000
(CT) 0030 0.030 0.030
Ronozyme® WX (Xyl) 0.02d 0.02d 0.02d
RM - Raw al
Ext. Hipro Soya Meal - Extruded Hipro soya meal (and extruded high protein
soybean meal)
Lysine HCl - (lysine hydrochloride) and Methionine DL (a
racemic e of the methionine D and L isomers) amino acids
Threonine - an amino acid
Dicalcium phosphate, sodium bicarbonate, and salt (sodium chloride) are ly used
nutrients
TM — Blank Premix for Broiler Formulation is the premix of vitamins and trace elements listed in
Table 2.
Ronozyme® P5000 (CT) and Ronozyme® WX (Xyl) are commercial names for enzymes that are
commonly used in wheat-based feeds, specifically:
Ronozyme® P5000 (CT) is a coated phytase enzyme
Ronozyme® WX is a xylanase
Reference is also made to Aviagen Ross 308 Broiler Nutrition Specifications 2014
documentation as examples of r diets
Table 2 provides the details of the TM Blank Premix for Broiler Formation listed in the
ingredients in Table l.
Table 2
Nutrient Analysis
USAGE 4.0000
VIT A 13.5000
VIT D3 5.0000
VIT E 100.0000
VIT B1 3 .0000
VIT B2 10.0000
VIT B6 3.0000
VIT B12 30.0000
HETRA 5.0000
NICO 60.0000
PANTO 15,0000
FOLIC 1.5000
BIOTIN 251.0000
CHOLCHL 250.0000
FE 0
MN 100.0000
CU 10.0000
ZN 80.0000
I 1.0000
SE 0.2500
MO 0.5000
*CA/USA 24.9103
*ASH/USA 74.3901
Tables 3 - 8 provide information regarding a trial experiment (Trial 1) carried out by the
Applicant. Trial 1 concerned the performance and the up-regulation of certain commensal
bacteria in GOS test treatments.
Trial 1
Trial design, measures and analysis
o Objective(s): Indicate optimum %(w/w) inclusion rate of galacto-oligosaccharides,
reduce and vary the galacto-oligosaccharides %(w/w) inclusion rate in the different feed
periods over the lifetime of the bird. The initial objective of the trial was to investigate the
effect of NutrabioticTM GOS L on the broiler microbiota by NGS and metagenomic
is (along with analyses of gut morphology and changes in immune fiinction
se).
Samples for the analysis of gut morphology are stored in dehyde ng
Results from NGS and metagenomic analysis of the caecal microbiota, along with
changes in immune fiJnction response (as ined through the up/down regulation
of cytokines and chemokines) will be available in the coming weeks.
0 Product: Nutrabiotic® GOS L — a G08 50% syrup containing approximately 72 %(w/w)
dry solids
0 Base diet: wheat-based (xylanase and phytase included), no coccidiostat
0 Type of bird: male Ross 308 (good chicks from strong 35 week old breeders)
0 Number of treatments: 1 X control + 5 X GOS tests
y Control
0 Feed screened for Salmonella prior to arrival of birds to ensure no contamination at feed
mill.
0 Birds screened on l for Salmonella and during the trial for both Campylobacter and
Salmonella.
Relevant facts/observations
General
0 Bird health was good with one bird suffering from hip dislocation and another suffering
from sudden death. No comments were received concerning gut lesions.
Performance
0 NutrabioticTM GOS L improved performance in terms of rate of weight gain with overall
the best performance appearing to be for the higher GOS inclusion rate being fed
throughout the growth period (P < 0.05). These improvements are maintained in the Test
treatments.
° The nce intervals of the weight data are quite wide, especially when sample
numbers are sed.
0 It appears NutrabioticTM GOS L es FCR for all treatments.
Standard microbiological analyses
0 rd microbiological methods were used to analyse on caecal samples, by standard
microbiological methods:
° obacler counts (CCDA plates, micro-aerobic incubation at 42 0C for 48 h,
using the Miles and Misra method);
° lactic bacteria counts (MRS plates, anaerobic incubation at 30 °C for 48 h);
° coliform counts (MacConkey no.3 plates, incubation at 37 °C for 24 h).
Microbiota analyses
0 DNA was extracted from the caecal microbiota, targeted amplicon sequencing was
employed using 16S RDNA (the gene for bacterial 16S rRNA) as a marker and molecular
phylogenetic methods (amplification, sequencing, grouping sequences into OTUs, and the
identification of OTUs) are used to infer the composition of the microbial community.
0 Alpha-diversity (number or richness) of taxa were quantified by the Simpson Index for
each treatment with good precision (as shown by asymptotic ction curves) and
showed no difference between each ent, as was expected.
0 Beta-diversity, which describes how many taxa are shared between treatments (a
similarity score and represented by the Yue and n theta similarity coefficient), gave
different results:
0 there was a significant difference (P < 0.0010) was found between the GOS[+] and
GOS[—] groups (taken as a whole); ,
° other es, including AMOVA (analysis of molecular variance) ed
these significant differences with the magnitude of the ity being: GOS
3.37% > GOS 1.685% > control with corresponding significance: (GOS 3.37% -
GOS 1.685%) > (GOS 1.685% - control);
a graphical representation of dissimilarities were shown as non-metric
multidimensional scaling plots based on dissimilarity es built from the Yue
and Clayton theta coefficients.
0 Metastats (White el al., 2009) was used to determine whether there are any OTUs that are
differentially represented between the different treatments:
° between the GOS[+] and GOS[-] groups (taken as a whole) 42 OTUs were
identified as significant.
Subsequent bioinformatics analyses
The major different OTUs in GOS[+] and GOS[—] groups have been identified, with the following
candidate organisms identified as being GOS responsive. Identification was based on OTUs
identified from 16S rDNA sequences from the V4 region of the microbiome. It is not possible to
obtain more information of exact bacterial subspecies, and in some cases species, without a more
complete analysis of the specific ial genome. The identification ed represents the
nearest match from the SILVA rRNA database (16S rRNA gene sequences were aligned against a
reference ent based on the SILVA rRNA database and red into operational
taxonomic units (OTUs) with an average neighbor clustering thm. The nearest 16S rRNA
gene sequence identities to the OTUs are reported on the basis of BLASTn searches if data
matches are from type cultures with a BLAST identity 299%.):
o bacierium animalis subsp. lactis str. V9
0 Collinsella Zanakaei str. YIT 12064
0 Ruminococcus s str, ATCC 27756
0 Lactobacillus reuteri str. BCS 136
o Anaeroslipes sp. str. 35-7
0 Lactobacillus crispatus str. ST]
0 Pediococcus actici
o Faecalibacterium prausnitzil'
Conclusions
In conclusion it was shown that:
0 there was an improvement in performance data, against the control, was seen in test
treatments containing Nutrabiotic® GOS Syrup, particularly at the higher dose rate of
3.37 %(w/w);
- there was no significant difference n the "richness" of taxa (alpha—diversity) for
each treatment, which is to be expected;
0 there was a significant different n the number of taxa shared between between
groups (beta-diversity) based on the inclusion of GOS in the diet. this allowed
identification of bacteria that were “responsive to Nutrabiotic® G08.
Table 3 provides a list of ients used in a poultry feed as part of Trial 1
Table 3
CON CON CON GOS GOS GOS GOS GOS GOS
TR TR TR 3.37 3.37 3.37 1.68 1.68 1.68
L: L: L: 0%: 0%: 0%: 5%: 5%: 5%:
ROS ROS ROS ROS ROS ROS ROS ROS ROS
S S S S S S S S S
308 308 308 308 308 308 308 308 308
BROI BROI BROI BRO BRO BRO BRO BRO BRO
LER LER LER ILER ILER ILER ILER ILER ILER
2015 2015 2015 2015 2015 2015 2015 2015 2015
STA GRO FINIS STA GRO FINI STA GRO FINI
RTE WER HER RTE WE SHE RTE WE SHE
R R R R R R R
59.99 60.71 66.31 54.0 54.7 60.3 57.0 57.7 63.3
2 WHEAT 9 6 9 16 23 37 03 19 24
EXT. HIPRO SOYA
54 MEAL 32.5 30.8 25.3 33.9 32.2 26.7 33.2 31.5 26.0
LIMESTONE
60 GRANULES 0.60 0.40 0.40 0.60 0.40 0.40 0.60 0.40 0.40
69 SOYABEAN OIL 3.65 5.52 5.60 4.88 6.76 6.84 4.27 6.14 6.22
0.26 0.08 0.09 0.28 0.10 0.10
106 LYSINE HCL 0.296 0.119 0.123 4 7 2 0 3 7
0.36 0.26 0.23 0.36 0.26 0.23
107 METHIONINE DL 0.362 0.263 0.231 6 7 4 4 5 2
DICALCIUM
110 PHOSPHATE 1.59 1.28 1.12 1.61 1.30 1.14 1.60 1.29 1.13
SODIUM 0.24 0.16 0.17 0.25 0.17 0.18
126 BICARBONATE 0.269 0.188 0.193 9 9 3 9 9 3
0.17 0.23 0.22 0.16 0.22 0.22
273 SALT 0.150 0.210 0.210 0 0 0 0 0 0
0.12 0.04 0.04 0.12 0.04 0.04
275 THREONINE 0.134 0.054 0.054 5 4 4 9 9 9
TMB TM - Blank Premix 0.40 0.40 0.40 0.40 0.40 0.40
LANK for Broiler Formulation 0.400 0.400 0.400 0 0 0 0 0 0
PROM NUTRABIOTIC 3.37 3.37 3.37 1.68 1.68 1.68
OV GOS SYRUP 0.000 0.000 0.000 0 0 0 5 5 5
RONO_ RONOZYME 0.03 0.03 0.03 0.03 0.03 0.03
P5 P5000 (CT) 0.030 0.030 0.030 0 0 0 0 0 0
RONO_ me WX 0.02 0.02 0.02 0.02 0.02 0.02
WX (XyI) 0.020 0.020 0.020 0 0 0 0 0 0
Specification
[VOLUME] 100 100 100 100 100 100 100 100 100
88.10 88.18 88.06 87.7 87.7 87.6 87.9 87.9 87.8
Dry matter 5 9 6 05 90 67 05 90 67
6.84 8.67 8.71 6.28 8.09 8.13
Oil 'B' 5.707 7.526 7.566 4 2 3 0 9 9
Crude Protein (GP) 22.00 21.00 19.01 21.9 20.9 19.0 21.9 20.9 19.0
(%) 2 4 9 91 90 08 95 97 12
2.63 2.60 2.61 2.70 2.67 2.68
Fibre (%) 2.775 2.745 2.749 7 8 1 6 7 0
.81 5.23 4.85 5.80 5.23 4.85
Ash (%) 5.808 5.236 4.858 0 9 0 9 8 9
1.42 1.23 1.09 1.42 1.23 1.09
Lysine (%) 1.430 1.240 1.091 9 9 1 9 9 1
0.69 0.58 0.52 0.69 0.58 0.52
Methionine (%) 0.691 0.582 0.521 5 6 4 3 4 2
Methionine + 1.07 0.95 0.86 1.07 0.95 0.86
Cystine (M+C) (%) 1.070 0.950 0.861 0 0 0 0 0 0
0.27 0.26 0.23 0.27 0.26 0.23
Tryptophan (%) 0.270 0.261 0.235 1 2 6 0 1 5
0.94 0.82 0.74 0.93 0.83 0.74
Theonine (%) 0.940 0.830 0.741 0 9 0 9 0 0
1.05 0.89 0.83 1.05 0.88 0.83
m (%) 1.047 0.886 0.834 2 2 9 0 9 6
Total Phosphorus 0.67 0.60 0.56 0.67 0.61 0.56
(T:PHOS) (%) 0.677 0.613 0.565 2 7 0 5 0 2
Available
Phosphorus (AzPHOS) 0.50 0.45 0.42 0.50 0.45 0.42
(%) 0.500 0.450 0.420 0 0 0 0 0 0
0.32 0.32 0.32 0.32 0.32 0.32
Salt (%) 0.319 0.322 0.326 3 6 1 1 4 8
0.16 0.16 0.15 0.15 0.16 0.16
Sodium (%) 0.158 0.160 0.161 0 2 9 9 1 2
2.90 3.84 3.89 2.61 3.54 3.59
Linoleic acid (%) 2.318 3.251 3.302 3 0 1 3 5 7
0.96 0.92 0.82 0.95 0.92 0.82
Potassium (%) 0.955 0.920 0.822 2 7 9 8 4 5
0.20 0.20 0.19 0.19 0.20 0.20
Chloride (%) 0.198 0.200 0.201 1 2 8 9 1 3
Broiler ME inc.
enzyme contribution 12.65 13.20 13.40 12.6 13.2 13.4 12.6 13.2 13.4
(MJ) 2 4 3 49 03 04 52 04 03
a poultry
digestible amino acid
values
1.30 1.12 0.98 1.30 1.12 0.98
Lysine (%) 1.306 1.122 0.984 5 1 4 6 2 4
0.63 0.53 0.47 0.63 0.52 0.47
Methionine (%) 0.635 0.528 0.473 8 1 5 6 9 4
Methionine + 0.94 0.83 0.75 0.94 0.83 0.75
Cystine (M+C) (%) 0.949 0.834 0.761 7 2 7 8 3 9
0.78 0.68 0.61 0.78 0.68 0.61
Theonine (%) 0.790 0.686 0.614 8 3 1 8 4 3
0.24 0.23 0.20 0.24 0.23 0.20
Tryptophan (%) 0.239 0.230 0.205 0 2 7 0 1 6
0.82 0.79 0.70 0.81 0.78 0.70
lsoleucine (%) 0.814 0.785 0.703 0 0 8 7 8 5
0.87 0.84 0.76 0.87 0.84 0.76
Valine (%) 0.874 0.843 0.759 7 7 2 5 5 0
0.49 0.48 0.43 0.49 0.48 0.43
Histidine (%) 0.496 0.479 0.429 9 1 2 7 0 1
1.29 1.24 1.09 1.28 1.23 1.08
Arginine(%) 1.275 1.225 1.077 3 3 5 4 4 6
Table 4 provides a comparison of the difference in speciation and Degussa y digestible
amino acid values from Table 3
Table 4
Differences
Specification Control - GOS_3.370% diets Control - GOS_1.685% diets
[VOLUME] Starter Grower Finisher Starter Grower Finisher
Dry matter 0.39934 0.39814 0.39946 3 1 0.19925
Oil 'B' 1.13654 4 1.14646 0.57313 0.57311 0.57315
0.01150 0.01328 0.00669 7
Crude Protein (CP) (%) 5 5 0.01178 0.00659 5 5
Fibre (%) 0.13749 0.13779 0.13746 0.06888 0.06891 0.06885
0.00262 0.00306 0.00726 - 0.00183 -
Ash (%) 8 2 6 0.00123 2 0.00124
0.00116 0.00119 7 0.00059 0.00059
Lysine (%) 6 7 3 7 0.0006 4
2 0.00371 0.00274 0.00185 0.00185 0.00086
Methionine (%) 9 2 1 7 5 9
0.00032 0.00028 0.00065 0.00014 4
Methionine + e (M+C) (%) 8 8 8 6 2 0.00084
0.00092 0.00090 0.00092 0.00045 0.00045 0.00045
Tryptophan (%) 1 9 2 5 4 6
0.00016 0.00085 0.00082 0.00042 0.00043 0.00042
Theonine (%) 1 9 6 8 1 5
0.00570 0.00570 0.00570 0.00285 0.00285 0.00285
Calcium (%) 8 4 9 2 2 2
0.00524 0.00527 0.00524 0.00263 0.00264 0.00263
Total Phosphorus (T:PHOS) (%) 9 9 6 8 1 5
Available Phosphorus (AzPHOS) 0.00012 0.00013 2
(%) 3 3 2 6.6E-05 6.7E-05 6.5E-05
0.00430 0.00429 0.00527 - 0.00214 0.00215
Salt (%) 9 9 1 0.00215 9 1
0.00188 0.00215 8 0.00094 0.00121 0.00094
Sodium (%) 8 6 2 3 3 3
0.58484 8 0.58984 0.29489 0.29488
Linoleic acid (%) 2 2 8 4 8 -0.2949
Potassium (%) 0.00686 0.00682 0.00687 0.00341 0.00341 0.00342
WO 02671
0.00292 0.00291 0.00296 0.00145 0.00145 0.00145
Chloride (%) 3 6 3 9 7 9
Broiler ME inc. enzyme contribution 0.00298 0.00074 0.00066 0.00030 0.00043 0.00037
(MJ) 5 1 1 5 6 9
Degussa poultry digestible amino
acid values
0.00082 0.00085 0.00042 0.00042 0.00042
Lysine (%) 9 5 4.8E-05 6 9 3
- 0.00296 0.00198 8 0.00148 0.00049
Methionine (%) 8 4 8 4 1 1
0.00234 0.00333 0.00118 9 0.00217
Methionine + Cystine (M+C) (%) 3 0.00238 3 8 2 8
0.00205 0.00304 0.00153 0.00153 0.00153
Theonine (%) 3 0.00307 3 4 6 2
0.00171 0.00170 0.00171 0.00085 0.00085 0.00085
Tryptophan (%) 7 7 8 4 3 5
0.00506 0.00510 0.00253 - 0.00253
Isoleucine (%) 1 4 4 5 0.00253 8
0.00336 0.00332 0.00337 0.00166 0.00166 -
Valine (%) 8 8 2 6 2 0.00167
0.00251 0.00249 0.00251 0.00124 0.00124 0.00125
ine (%) 7 6 9 9 7 1
0.01809 - 0.01809 0.00902 0.00902 0.00903
Arginine (%) 3 0.01805 7 7 3 1
Table 5 provides a summary of the treatments used in Trial 1
Table 5
Group 1 l starter 1 to 10 days
Control grower l l to 24 days
finishe
Control r 25 to 3 5 days
Group 2 3 .3 7 %(w/w) GOS r l to 10 days
Control feed grower l l to 24 days
finishe
Control feed r 25 to 3 5 days
WO 02671
Group 3 3.37 %(w/w) GOS starter 1 to 10 days
3.37 %(w/w) GOS grower 11 to 24 days
finishe
Control feed r 25 to 35 days
Group 4 3.37 %(w/w) GOS starter 1 to 10 days
3.37 %(w/w) GOS grower 11 to 24 days
finishe
3.37 %(w/w) GOS r 25 to 35 days
Group 5 Control feed starter 1 to 10 days
Control feed grower 11 to 24 days
finishe
3.37 %(w/w) GOS r 25 to 35 days
Group 6 1.685 %(w/w) GOS starter 1 to 10 days
1.685 %(w/w) GOS grower 11 to 24 days
finishe
1.685 %(w/w) GOS r 25 to 35 days
Table 6 provides the weight (g) of the broilers used in Trial 1
Table 6
Group Weight (g)
0 8 15 22 28 35 Days
G1 40.8 180.0 498.7 934.5 1411.5 2012.0 (g) mean
Total
2.87 13.61 56.25 105.33 176.08 213.64 stdeV
G2 40.9 188.0 556.4 1032.9 1623.7 2270.7 (g) mean
Total
2.85 13.76 61.16 138.65 168.04 253.01 stdeV
G3 40.9 190.1 531.6 1009.1 1554.1 2126.6 (g) mean
Total
2.96 15.80 54.51 119.53 190.86 210.33 stdeV
G4 41.3 183.5 562.5 1030.5 1608.8 2360.8 (g) mean
Total
2.88 14.97 64.93 120.45 155.29 144.36 stdeV
G5 40.2 185.2 517.0 923.1 1491.1 2197.5 (g) mean
T0 at l
2.71 20.25 58.53 127.35 165.93 344.96 stdeV
G6 40.5 187.9 526.2 974.8 1540.0 2173.5 (g) mean
Total
3.14 22.36 57.52 119.99 170.21 216.79 stdeV
Table 7 provides the feed consumption of the broilers used in Trial 1
Table 7
Group Feed consumption (g)
0 10 15 22 25 28 35 Days
G1 230 273 657 411 453 1093 Interval (g) mean
12 39 86 70 109 1 17 Total stdev
230 503 1160 1571 2024 3117 Cumm. (g)
G2 230 305 725 452 500 1209 Interval (g) mean
26 9O 35 85 102 Total stdev
230 535 1260 1712 2212 3421 Cumm. (g)
G3 236 270 713 415 468 1292 Interval (g) mean
13 33 82 62 92 71 Total stdev
236 506 1219 1634 2102 3394 Cumm. (g)
G4 224 300 740 461 515 1356 Interval (g) mean
8 22 82 59 69 55 Total stdev
224 524 1264 1725 2240 3596 Cumm. (g)
G5 222 289 717 428 495 1225 Interval (g) mean
12 32 84 58 93 105 Total stdev
222 511 1228 1656 2151 3376 Cumm. (g)
G6 238 241 719 450 502 1188 al (g) mean
18 42 76 56 91 54 Total stdev
238 479 1198 1648 2150 3338 Cumm. (g)
Table 8 provides the cumulative feed consumption ratio of the broilers used in Trial 1
Table 8
Weight
Group (g)
0 8 15 22 28 35 Days
G1 0.890 1.000 1.240 1.434 1.549 Total
G2 0.850 0.962 1.220 1.363 1.507 Total
G3 0.870 0.953 1.210 1.353 1.596 Total
G4 0.860 0.948 1.220 1.393 1.524 Total
G5 0.850 0.990 1.330 1.442 1.537 Total
G6 0.880 0.897 1.230 1.396 1.536 Total
Tables 9 — 20 provide information regarding a trial experiment (Trial 2) carried out by the
Applicant. Trial 2 ned the use obacillus crispatus DC21.1 (NCIlVfl3 42771) as a
probiotic
Trial 2
Objectives
To test the persistence and efficacy of Lactobacillus crispatus was provided as a probiotic to
male Ross 308 broilers fed a standard wheat-based feed in the presence and absence of the
galacto-oligosaccharide contain product - Nutrabiotic® GOS.
Design
4 ents each ning 20 —24 male Ross 308 broiler that were fed a rd wheat—based
starter, grower and finisher feed. The feeds contained no antibiotic or coccidiostat products, but
Nutrabiotic® G08 and Lactobacillus crispatus DC21.1 (NCIlVfl3 42771). Details of the feed are
given below and in the associated files. The trial was carried out for 35 days, and the
acillus crispaz‘us was added on day 9 by cloacal gavage with 107 cfi1 (viable cells) being
administered in 0.10 ml MRD (maximum recovery diluent) from a syringe that had been
preloaded in an anerobic cabinet.
0 Group 1: Pen 6 iotic® GOS Lactobacillus crispalus
0 Group 2: Pen 7 iotic® GOS not added
0 Group 3: Pen 8 not added not added
0 Group 4: Pen 9 not added Lactobacillus tus
Results
There was only a single addition of the Lactobacillus crispatus was added on day 9 after bird
placement. Persistence of the Lactobacillus crispatus was determined as follows:
0 DNA extractions were made from from caeca contents (MPBio kit) with concentration
ranges of 80-250 ng/ul,
0 DNA concentrations were normalised;
o qPCR was used, with absolute quantification using a standard curve based on extracted
Lactobacillus crispatus DNA at different dilutions.
The concentration of the Laclobacillus crispalus, which is a commensal strain, when
administered on day 9 after bird placement was present at the end of the trial at 1.9 - 2.9 X the
concentration in treatments where it had not been added by oral gavage.
Whilst this was not a large trial, lacking statistical power, and the s were not significant in
that P > 0.05, the increase in bird weight at 35 days was greatest for group 1 (Nutrabiotic® GOS
+ Lactobacillus tus) with, in some comparisons P < 0.10.
Conclusions
Lactobacillus crispatus DC2l.l (NCIMB 42771) persists in the broiler caecum at the end of the
ment period, at day 35, when administered at day 9. The probiotic was present a
concentrations of 1.9 - 2.9 x the concentration in control treatments. Whilst the trial lacked
statistical power, and the results were not significant in that P > 0.05, the increase in bird weight
at 35 days was greatest the test group (Nutrabiotic® GOS + Lactobacillus crispatus) with, in
some comparisons P < 0.10.
Table 9
Table 9 provides the performance data of Trial 2 — Group 1, Pen 6
WO 02671
Group Lactobacillu
1 Pen 6 GOS2 s crispatus
08/11/1 18/11/1 28/11/1 05/12/1 13/12/1
Date 6 15/11/16 6 6 6 6
Time (days) 0 7 10 20 27 35
Bird Weight Weight Weight Weight Weight Weight
(g) (g) (g) (g) (g) (g)
1 41 214 262 740
2 40 198 345 985 1321 1931
3 35 189 323 803
4 39 198 313 876 1159 1745
38 219 332 937 1432 2270
6 3 7 181 297 715
7 40 183 282 758 1298 1803
8 41 185 302 792 1379 2240
9 34 218 299 782
41 171 292 742 1240 1958
11 43 173 313 925 1202 1998
12 38 191 272 746
13 3 5 186 276 717
14 39 203 230 862
39 196 298 867
16 37 147 204 617
17 39 177 263 862 1372 2260
18 41 171 319 986 1361 2080
19 40 196 330 828 1294 2040
41 149 251 779
average weight 38.9 187.3 290.2 816.0 1305.8 2032.5
st. deV. 2.4 19.6 35.8 96.5 85.5 184.4
RSD (%) 6.1% 10.5% 12.3% 11.8% 6.5% 9.1%
cum. feed per
bird (g) 163 339 1023 1896 3196
FCR 0.870 1.168 1.254 1.452 1.572
Table 10 provides the performance data of Trial 2 — Group 2, Pen 7
Table 10
Grou Pen 7 GOS2
201 18/11/201 28/11/201 05/12/201 13/12/201
Date 08/11/16 6 6 6 6 6
Time (days) 0 7 10 20 27 35
Bird Weight Weight Weight Weight Weight Weight
(g) (g) (g) (g) (g) (g)
1 36 178 295 782
2 33 148 248 621
3 35 179 262 757 1042 1567
4 35 148 234 628
38 179 256 799 1317 2018
6 40 189 254 892
7 41 168 256 766 1112 1787
8 41 175 263 792 1282 1946
9 38 168 299 717
38 172 275 778
11 41 164 329 788
12 37 161 308 746 1082 1632
13 38 166 282 781
14 39 201 320 862 1192 1769
40 197 324 898 1186 1738
16 39 154 294 728 1132 1670
17 38 166 242 719
18 43 207 276 986 1372 2149
19 42 204 355 978 1524 2289
40 176 251 779
averag
weight 38.6 175.0 281.2 789.9 1224.1 1856.5
st. dev. 2.5 17.4 33.3 95.7 149.3 236.2
(%) 6.6% 9.9% 11.8% 12.1% 12.2% 12.7%
cum.
feed per
bird (g) 158 336 939 1699 2945
FCR 0.900 1.193 1.189 1.388 1.586
Table 11 provides the mance data of Trial 2 — Group 3, Pen 8
Table 11
Grou
p 3 Pen 8
08/11/20 15/11/20 18/11/20 28/11/20 05/12/20 13/12/20
Date 16 16 16 16 16 16
Time (days) 0 7 10 20 27 35
Bird Weight Weight Weight Weight Weight Weight
(g) (g) (g) (g) (g) (g)
1 40 214 319 900 1492 2172
2 43 198 364 985 1424 2020
3 39 189 294 658 1156 1932
4 39 198 249 626 1154 2002
36 219 264 626 1176 1780
6 37 181 290 705
7 37 183 264 692
8 39 185 293 772 1294 1789
9 39 218 294 737 1094 1693
43 171 285 870 1482 2109
11 44 173 307 930 1374 2039
12 38 191 256 705
13 42 186 283 930 1336 1720
14 42 203 314 893
38 196 258 753 1161 1803
16 41 147 310 857
17 42 177 303 870 1294 1720
18 41 171 287 802
19 40 196 297 840 1424 2123
38 169 283 781
21 37 149 249 589
22 41 182 287 802
23 30 190 282 858 1482 2163
24 42 171 267 799
average
weight 39.5 185.7 287.5 790.8 1310.2 1933.2
st. deV. 3.0 18.5 25.8 107.3 141.0 177.6
RSD (%) 7.6% 10.0% 9.0% 13.6% 10.8% 9.2%
cum. feed per
bird (g) 158 328 999 1760 2932
FCR 0.848 1.142 1.263 1.344 1.517
Table 12 provides the mance data of Trial 2 — Group 4, Pen 9
Table 12
Lactobacill
Grou us
p 4 Pen 9 crispatus
08/11/20 18/11/20 28/11/20 05/12/20 13/12/20
Date 16 15/11/2016 16 16 16 16
Time (days) 0 7 10 20 27 35
Bird Weight Weight Weight Weight Weight Weight
(g) (g) (g) (g) (g) (g)
1 41 214 272 720
wo 2018/002671 2017/051949
2 40 198 230 715 1084 1718
3 35 189 244 739
4 39 198 315 703
38 219 261 658 1078 1700
6 37 181 266 679 1061 1676
7 40 183 237 691
8 41 185 274 668 1180 1890
9 34 218 306 714 1089 1525
41 171 315 802
11 43 173 287 791 1324 2015
12 38 191 343 920 1422 2080
13 35 186 350 952 1548 2300
14 39 203 330 872 1361 2052
39 196 290 819 1248 1825
16 37 147 272 719 1261 1932
17 39 177 263 720
18 41 171 297 752
19 40 196 280 742 1214 1840
41 149 281 779
21 38 185 309 799 1312 1970
22 36 152 244 791
23 40 188 276 801 1328 1890
24 41 207 311 895
average
weight 38.9 186.5 285.5 768.4 1250.7 1886.6
st. deV. 2.3 19.7 32.3 79.6 144.4 197.2
RSD (%) 5.9% 10.6% 11.3% 10.4% 11.5% 10.5%
cum. feed per
bird (g) 158 323 938 1719 2872
FCR 0.847 1.131 1.221 1.375 1.522
#44444
Table 13 provides the t—Test data from Trial 2
Table 13
t-Test
Test Time (days)
0 7 10 20 27 3 5
P—values
vs 2 0.7011 0.0433 0.4151 0.3959 0.1506 0.0797
Gp 1
vs 3 0.4711 0.7901 0.7737 0.4232 0.9308 0.1974
Gp 1
vs 4 0.9718 0.9058 0.6559 0.0801 0.2940 0.0802
Table 14 provides the feed consumption data from Trial 2 — Group 1, Pen 6
Table 14
Group 1 Pen 6 GOSZ acillus crispatus
Date Age feed feed feed cum. feed no of feed cum.
start end consumed consumed birds per feed
bird per
bird
(daYS) (g) (g) (g) (g) (g) (g) (55)
08/11/2016 0 4000 740
/11/2016 7 5000 1480 3260 3260 20 163 163
18/11/2016 10 14600 920 3520 6780 20 176 339
28/11/2016 20 12000 3274 13680 20460 20 684 1023
05/12/2016 27 16000 3000 8726 29186 10 873 1896
13/12/2016 35 13000 42186 10 1300 3196
Table 15 provides the feed consumption data from Trial 2 — Group 2, Pen 7
Table 15
Group 2 Pen 7 GOSZ
Date Age feed feed feed cum. feed no of feed cum.
start end consume consume birds per feed
d d bird per
bird
(dayS) (g) (g) (g) (g) (g) (g) (g)
08/11/201
6 0 4000 850
6 7 5000 1440 3150 3150 20 158 158
18/11/201
6 10 14600 2526 3560 6710 20 178 336
28/11/201
6 20 12000 4400 12074 18784 20 604 939
05/12/201
6 27 16000 3540 7600 263 84 10 760 1699
13/12/201
6 35 12460 38844 10 1246 2945
Table 16 provides the feed consumption data from Trial 2 — Group 3, Pen 8
Table 16
Group 3 Pen 8
Date Age feed feed feed cum. feed no of feed cum.
start end consume consume birds per feed
d d bird per
bird
(dayS) (g) (g) (g) (g) (g) (g) (g)
6 0 4000 220
/11/201
6 7 5000 900 3780 3780 24 158 158
18/11/201
6 10 16200 109 4100 7880 24 171 328
28/11/201
6 20 12000 1338 16091 23971 24 670 999
05/12/201
6 27 20000 3599 10662 34633 14 762 1760
13/12/201
6 35 16401 51034 14 1172 2932
Table 17 provides the feed consumption data from Trial 2 — Group 4, Pen 9
Table 1 7
Group 4 Pen 9 Lactobacillus crispatus
Date Age feed feed feed cum. feed no of feed cum.
start end consumed consumed birds per feed
bird per
bird
(den/S) (g) (g) (g) (g) (g) (g) (g)
08/11/2016 0 4000 210
2016 7 5000 1040 3790 3790 24 158 158
18/11/2016 10 16200 1433 3960 7750 24 165 323
28/11/2016 20 12000 1063 14767 22517 24 615 938
05/12/2016 27 20000 3865 10937 33454 14 781 1719
13/12/2016 35 16135 49589 14 1153 2872
Table 18 is the feed formulation used in Trial 2, days 0 — 10
Table 18
Group 0 - 10 days
Starter feed (sieved
crumb)
L. crispatus GOS N0. . intake Cumm. intake
birds
(kg/te) (kg/bird) (kg/trt) (kg/bird) (kg/trt)
2 23.860 20 0.294 5.88 0.294 5.88
3 24 0.294 7.06 0.294 7.06
4 + 24 0.294 7.06 0.294 7.06
Totals 88 25.9 25.9
Table 19 provides the feed formulation used in Trial 2, days 11 - 24
Table 19
Group 1 1-24 days
Grower feed (pellets 3 mm diam.)
L. No.
crispatus GOS birds Intake Cumm. intake
(kg/te) (kg/bird) (kg/trt) (kg/bird) (kg/trt)
1 + 11.93 20 1.312 26.24 1.606 32.12
2 - 11.93 20 1.312 26.24 1.606 32.12
3 - 24 1.312 31.488 1.606 38.544
4 + 24 1.312 31.488 1.606 38.544
Totals 88 115.456 141.328
Table 20 is the feed formulation used in Trial 2, days 25 - 35
Table 20
Group 25-35 days
Finisher feed (pellets 3 mm diam.)
L. No.
crispatus GOS birds Intake Cumm. intake
(kg/te) (kg/bird) (kg/trt) (kg/bird) (kg/trt)
1 + 0 20 1.904 38.08 3.51 70.2
2 - 0 20 1.904 38.08 3.51 70.2
3 - 24 1.904 45.696 3.51 84.24
4 + 24 1.904 45.696 3.51 84.24
Totals 88 167.552 308.88
Table 21 provides a ption ofNutrabiotic® GOS L with which the composition of the
invention may comprise as a tic.
Table 21
Nutrabiotic® GOS L
2017/051949
Description : galacto-oligosaccharide syrup.
Typical analysis : dry matter: 75 %(w/w) of which galacto—oligosaccharides: 59 %(w/w DM),
lactose: 17%(w/w DM), glucose: 17%(w/w DM), galactose: 7%(w/w DM)
Sensorial : clear yellow to colourless liquid syrup, slightly sweet taste.
Specification Method of analysis
Chemical and physical:
Dry matter 74 :: 2 %(w/w) IDF 26A (1993), 21/2 h
102i2°C
Galacto-oligosaccharides 2 57 %(w/w DM)
Lactose S 23 %(w/w DM) Dairy Crest methods:
, issue 01, Aug-2014
Glucose S 22 %(w/w DM)
C-T. 10, issue 06, Mar-2016
Galactose 2 0.8 %(w/w DM)
Total Nitrogen S 0.1 %(w/w DM) IDF 20B , Kjeldahl
Sulphated ash S 0.3 %(w/w DM) AOAC 17 ed. (2000)
930.30,
sulphated = 550°C to
constant weight
1000-5000 mPas HAAKE
3.1 - 38 ISO 10523 (1994),
potentiometric (10 % w/w)
Microbiological:
Total plate count S 1000 cfu/g IDF 100B (1991), PCMA
72h 30°C
Yeasts S 50 cfu/g IDF 94B (1990), OGYE 5
days 25°C
Moulds S 50 cfii/g IDF 94B (1990), OGYE 5
days 25°C
Enierobacteriaceae absent in 1 g BDI 23, VRBG 24h 30°C
Escherichia coli absent in 5 g IDF l7OA—l (1999), LSTB
48h 37°C, ECB 48h 44°C
elleae absent in 25 g IDF 93B (1995)
Packaging: 1200 kg IBC
Storage:
keep in clean, dry and dark
conditions, keep away from
strongly odorous materials.
Shelf life:
18 months after production
date.
Table 22 provides recommendations based on typical feeding regimes and ones that have
been used in both research and commercial trials. They can be modified as required. A
comparison between broilers and piglets is also provided.
Table 22
Batch number - Nutrabiotic® GOS L batch no. AQ6215
Dry matter 74.2 %(w/w)
Water 25.8 %(w/w)
Broilers
Starter feed day 0 - 10 24.70 kg per metric tonne of complete feed
Grower feed day 11 - 24 12.35 kg per metric tonne of complete feed
er feed day 25 - not generally required
Piglets
Creep (pre—starter) feed day 10 - weaning 15.1 kg per metric tonne of te feed
Weaning day 28
Starter feed day 28 - 35 9.1 kg per metric tonne of complete feed
Link feed day 35 — 49 91 kg per metric tonne of complete feed
Grower feed day 49 - 63 as required
Notes
Dose rates for iotic® GOS L are given for the syrup product as is.
Table 23 provides primers sequence 5’-3’ for the genes expression determined by qPCR.
Table 23
Target gene Primer sequence ) Product size NCBI Accession Reference
(bp) number
GAPDH F: 343 NM_204305.1 Nang er a].
GACGTGCAGCAGGAACACTA (2011)
R: TCTCCATGGTGGTGA
AGACA
IFN—y F 152 }U%_2051491
TJang a al
TGAGCCAGATTGTTTCGATG
(2011)
RgCTTGGCCAGGTCCATGATA
IL-lB F 272 DUM_2045241
GGATTCTGAGCACACCACAGT
Iqang a al
(2011)
TCTGGTTGATGTCGAAGATGT
11r4 F 186 bflfl_0010070791
CATCCGGATAGTGA Tqang et al
R: (2011)
TGACGCATGTTGAGGAAGAG
IL-10 F 203 }U%_0010044142
Nag a al
GCTGCGCTTCTACACAGATG
(2011)
RJTCCCGTTCTCATCCATCTTC
IL-6 F:GCTCGCCGGCTTCGA 71 46281 Biaiser a al
R: (2003)
GGTAGGTCTGAAAGGCGAAC
IL17-A F 68 }U%_2044601 I{eid a al
CATGGGATTACAGGATCGATG (2016)
RgGCGGCACTGGGCATCA
IL17-F F 78 )flfl_4262235 I{eid a a[
TGACCCTGCCTCTAGGATGAT (2016)
GGGTCCTCATCGAGCCTGTA
ChCXCLil F:CCGATGCCAGTGCATAGAG 191 }U%_2050181 Rasoli a al
R: (2015)
CCTTGTCCAGAATTGCCTTG
ChCXCLi2 F: TTCAGCTGCTCTGT 128 NM_205498.1 Rasoli er
R: (2015)
GCGTCAGCTTCACATCTTGA
Table 24 provides an estimate ofthe metabolizable energy values ofNutrabiotic® GOS L
in broilers and piglets.
Table 24
Batch number
Nutrabiotic® GOS L batch no. AQ6215
Dry matter 74.2 %(w/w)
Water 25.8 %(w/w)
Net Metabolizable Energy (NME): broilers
6.06 kJ/g Nutrabiotic® GOS L syrup product
1.45 kcal/g Nutrabiotic® GOS L syrup product
Net Metabolizable Energy (NME): piglets
7.26 kJ/g Nutrabiotic® GOS L syrup product
1.74 kcal/g iotic® GOS L syrup product
Notes
The NlVIE values are expressed per weight of the Nutrabiotic® GOS L product as is, i.e. the syrup
product that is added.
It is of course to be understood that the present invention is not intended to be cted to
the foregoing examples which are described by way of e only.
The present invention relates to compositions for use in the treatment and/or nutrition of
poultry, such as broiler chickens (Gallus gallus icus). However it is not beyond the scope
of the invention that the present invention may also relate to game birds such as grouse, pheasant
or quail, for example.
Claims (18)
1. A composition comprising: (i) a probiotic selected from one or more of the bacteria Bifz’dobacterium animalz’s, Collinsella Zanakaei, Lactobacillus reuteri, Anaerostipes, Laclobacillus crispatus, Pediococcus acidilactici, Lactobacillus pontis, Faecalz'bacz‘erium prausnitzz'i, Coprococcus cams, Roseburia inlestinalis, Anaeroslipes licus, Bulyricicoccus, Lactobacillusjohnsonii, andRuminococcus sp., and (ii) a prebiotic material.
2. A composition according to claim 1, wherein the one or more bacteria are ed from 15 Bifidobacterium animalis subsp. lactis str. V9, Collinsella tanakaei str. YIT 12064, Laclobacillus ri str. BCSl36, Anaeroslipes sp. str. 35-7, Lactobacillus z‘us str. STl, Lactobacillus crispaz‘us str. DC21, Lactobacillus crispaz‘us str. DC21.l (NCIlVIB 42771), Laclobacz'llus johnsonii DC22.2 (NCIMB 42772), Laclobacillus reuleri DClB4 (NCIlVfl3 42773), and Ruminococcus sp. DC3A4 (NCIlVfl3 42774).
3. A composition according to claim 1 or claim 2, wherein the composition ses two or more probiotics.
4. A composition according to claim 3, wherein the composition comprises two or more 25 probiotics in combination with only one prebiotic material.
5. A composition according to claim 4, wherein a first probiotic is taken from a group comprising specific ative anaerobic commensal bacteria, and a second probiotic is taken from a group comprising specific strictly anaerobic commensal bacteria.
6. A composition ing to any ing claim, wherein the tic material is substantially indigestible in the gastrointestinal system of a chicken.
7. A composition according to any preceding claim, wherein the prebiotic material is a polymeric saccharide.
8. A composition according to claim 7, wherein the polymeric saccharide is an oligosaccharide.
9. A composition according to claim 7 or claim 8, wherein the polymeric saccharide is selected from one or more of fructo-oligosaccharide, isomaltooligosaccharide, oligosaccharide, galactooligosaccharide, xylo-oligosaccharide, arabinoxylo- 10 oligosaccharide, glucooligosaccharide, soyoligosaccharide, pectic oligosaccharide, and
10. A composition according to any preceding claim, further comprising a nutrient food source.
11. A composition according to claim 10, wherein the nutrient food source is a source of protein, , amino acids, fat, or a combination of any one or more thereof.
12. A composition according to any preceding claim, n the composition is a starter feed 20 or grower feed,
13. A composition according to 12, n a starter feed comprises a prebiotic in an amount between 55% to 95% (w/w) solids concentration syrup. 25
14. A composition according to any of claims 12 or 13, wherein a starter feed comprises a tic added at a dose rate between 0.50% to 5.00% (w/w complete starter feed).
15. A ition according to claim 12, wherein a grower feed comprises a prebiotic in an amount between 55% to 95% (w/w) solids concentration syrup.
16. A composition according to any of claims 12 or 15, wherein a grower feed comprises a tic added at a dose rate between 0.20% to 5.00% (w/w complete grower feed). WO 02671
17. A composition according to any preceding claim for use in the treatment of c bacterial disease in poultry.
18. A composition according to claim 17, wherein the enteric bacterial disease is infection by one or more of the following: Clostridium perfringens, Salmonella spp, pathogenic and toxigenic Escherichia coli (EPEC and ETEC). 19‘ A method of producing a composition according to any of the preceding claims.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1611486.0 | 2016-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ749545A true NZ749545A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Clavijo et al. | The gastrointestinal microbiome and its association with the control of pathogens in broiler chicken production: A review | |
Stanley et al. | Microbiota of the chicken gastrointestinal tract: influence on health, productivity and disease | |
Neubauer et al. | High-grain diets supplemented with phytogenic compounds or autolyzed yeast modulate ruminal bacterial community and fermentation in dry cows | |
WO2018002671A1 (en) | Composition for treatment and/or nutrition of poultry | |
Van der Hoeven-Hangoor et al. | Ileal microbiota composition of broilers fed various commercial diet compositions | |
Snel et al. | Dietary strategies to influence the gastro-intestinal microflora of young animals, and its potential to improve intestinal health | |
Reyes-Becerril et al. | Single or combined effects of Lactobacillus sakei and inulin on growth, non-specific immunity and IgM expression in leopard grouper (Mycteroperca rosacea) | |
KAEVSKA et al. | Effect of sodium humate and zinc oxide used in prophylaxis of post-weaning diarrhoea on faecal microbiota composition in weaned piglets. | |
US20240023576A1 (en) | Microbial compositions for fowl health and performance | |
TW201143631A (en) | Novel Enterococcus faecium LJS-01 and its use as probiotic | |
WO2010036876A2 (en) | Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota | |
Jin et al. | Consuming fermented distillers' dried grains with solubles (DDGS) feed reveals a shift in the faecal microbiota of growing and fattening pigs using 454 pyrosequencing | |
WO2019232284A1 (en) | Compostions and method of use for h5 competent bifidobacterium longum subsp. infantis | |
De Maesschalck et al. | Amorphous cellulose feed supplement alters the broiler caecal microbiome | |
Lu et al. | Effects of feed additives on the development on the ileal bacterial community of the broiler chicken | |
Dunislawska et al. | Transcriptome modulation by in ovo delivered Lactobacillus synbiotics in a range of chicken tissues | |
CN104736695A (en) | Non-pathogenic F18 E. coli strain and use thereof | |
CN116782771A (en) | Compositions and related methods for supporting companion animals having gastrointestinal disorders | |
Orso et al. | Changes in the ceca microbiota of broilers vaccinated for coccidiosis or supplemented with salinomycin | |
Sheoran et al. | Probiotic and prebiotic supplementation improving the production performance and immune characteristics of laying hens | |
CA2987013A1 (en) | Probiotic or prebiotic, method for producing same, microbial preparation, health food, and medicine | |
US11752178B2 (en) | Methods for the isolation of microbes with enhanced persistance and compositions with such microbes | |
Baffoni | Probiotics and prebiotics for the health of companion animals | |
Guo et al. | Effects of dietary β-1, 3-glucan addition on the growth performance, mRNA expression in jejunal barrier, and cecal microflora of broilers challenged with Clostridium perfringens | |
NZ749545A (en) | Composition for treatment and/or nutrition of poultry |